2016 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/21/16Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies
Collaboration designed to leverage Merus’ Biclonics® bispecific antibody technology to expand Incyte’s discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares; Merus eligible to receive potential development, regulatory and commercial milestones and sales royalties Merus conference call scheduled today at 8:30 a.m. ET, 2:30 p.m. CETWILMINGTON, DE AND UTRECHT, THE NETHERLANDS, December 21, 2016 – In... 
Printer Friendly Version
11/15/16Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies
European Patent Office Dismisses Arguments by Regeneron Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029 UTRECHT, The Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it received two favorable rulings for its European patent EP 2147594 B1 (the “‘594 patent”) by the Opposition Division of the European Patent Office (the ... 
Printer Friendly Version
11/10/16Merus to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday, November 17, 2016 at 11:20 PM GMT at the Waldorf Hilton in London, UK. A live webcast of the Jefferies presentation will be available on the Investor page of the Company's website. An archived prese... 
Printer Friendly Version
11/09/16Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant with Aquila BioMedical Ltd to Jointly Develop Immunological Assays for Identification of Novel Immunomodulatory Bispecific Antibodies
UTRECHT, The Netherlands and EDINBURGH, UK, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that it has been awarded  a €1.5 million EUREKA Eurostars grant (“iMOD-ReACT”) with Aquila BioMedical, Ltd. to jointly develop novel immunological assays supporting the selection of potent bispecific antibodies that positively modulate tumor immunity with superior potency and lowe... 
Printer Friendly Version
11/07/16Merus Announces Third Quarter 2016 Financial Results and Corporate Developments
UTRECHT, The Netherlands, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the third quarter ended September 30, 2016 and provided a review of recent accomplishments and clinical development plans. “We continued to execute on our clinical strategy during the third quarter, and we are well financed to achieve several key milestones in the coming qu... 
Printer Friendly Version
11/03/16Merus Strengthens Executive Management Team with the Appointment of John Crowley as Chief Financial Officer
Former CFO Shelley Margetson Elevated to Chief Operating Officer UTRECHT, The Netherlands, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of John Crowley as Chief Financial Officer. In this position, Mr. Crowley will lead Merus’ finance function reporting to Dr. Ton Logtenberg, Chief Executive Officer of Merus. He will be based in Cambridge, Massachuset... 
Printer Friendly Version
10/26/16Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer
UTRECHT, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of L. Andres Sirulnik, MD, PhD, to the position of Chief Medical Officer, where he will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Sirulnik will report to Ton Logtenberg, PhD, Chief Executive Officer of Merus, and will ... 
Printer Friendly Version
10/19/16Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership with CMC Service Agreement
UTRECHT, The Netherlands, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed milestone payment from Ono Pharmaceutical Co., LTD. (Osaka, Japan, ‘Ono’), under the ongoing collaboration between the two companies. The milestone was triggered as a result of pre-clinical confirmatory studies using the selected lead bispecific antibody can... 
Printer Friendly Version
08/31/16Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences: Ton Logtenberg, CEO, will present at the 2016 Credit Suisse Antibody Day on Wednesday, September 7 at 2:40 PM ET at Credit Suisse's offices at One Madison Avenue in New York City. Management will participate... 
Printer Friendly Version
08/10/16Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference
UTRECHT, The Netherlands, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17 at 2:30 PM ET at the Le Parker Meridien in New York City. A live webcast of the presentation will be available on the Investor page of the Company's website. An archived presentation will be a... 
Printer Friendly Version
08/08/16Merus Announces Second Quarter 2016 Financial Results and Reviews Recent Clinical Progress and Corporate Developments
UTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent accomplishments and clinical development plans. “We ended the second quarter with €71.1 million of cash and cash equivalents, which provides us with the funding to achieve several development milestones,... 
Printer Friendly Version
07/12/16Merus Announces First Quarter 2016 Financial Results and Highlights Recent Clinical Progress and Corporate Developments
Raises $53.3 Million in Successful Initial Public Offering Doses First Patient in Phase 1/2 Study of MCLA-117 in Patients with AMLUTRECHT, The Netherlands, July 12, 2016 (GLOBE NEWSWIRE) -- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the first quarter ended March 31, 2016 and provided an update on recent accomplishments and clinical development plans.“The past few months have been tran... 
Printer Friendly Version
06/01/16Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing TechnologyBERLIN & UTRECHT, The Netherlands, June  01, 2016  (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly announced that Merus has signed a commercial multi-product license agreement for ProBioGen's GlymaxX® ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) enhancement technology. Under the terms of the agreement, Merus has obtained non-exclusive use of GlymaxX® technology for ... 
Printer Friendly Version
05/31/16Merus N.V. Announces Closing of Partial Exercise of Underwriters' Over-Allotment Option
UTRECHT, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus") (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public offering in the amount of an additional 639,926 common shares at the initial public offering price of $10.00 per share. The sale of the additional shares closed on May 26, 2... 
Printer Friendly Version
05/24/16Merus N.V. Announces Closing of Initial Public Offering
UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share.  The shares began trading on The NASDAQ Global Market under the ticker symbol “MRUS” on May 19, 2016. All of the common shares in the offering were offered by Merus.  The net proceeds to Merus from the sale of shares in the offering are estimated to be approxim... 
Printer Friendly Version
05/18/16Merus Announces Pricing of Initial Public Offering
UTRECHT, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- Merus B.V. (“Merus”) today announced the pricing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share, before underwriting discounts and commissions. All of the common shares are being offered by Merus. In addition, Merus granted the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the initial public offering price.  The shares are expecte... 
Printer Friendly Version
05/04/16Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating Bispecific Antibody Candidate MCLA-117 in Patients with AML
UTRECHT, The Netherlands (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first patient has been dosed in the Company's Phase 1/2 clinic al trial evaluating MCLA-117 as a potential treatment of patients with acute myeloid leukemia (AML). MCLA-117 is a bispecific antibody candidate, which the Company refers to as Biclonics, that is designed to recruit and activate an AML patient's own T-cells t... 
Printer Friendly Version
04/15/16Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting
MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid TumorsUTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics), today announced a scheduled poster presentation at the American Association for Cancer Research (AACR) 2016 Annual Meeting being held April 16-20, 2016 in New Orleans. Merus will be presenting interim... 
Printer Friendly Version
03/09/16Merus Announces Issuance of Three U.S. Patents Strengthening its Biclonics® Technology Platform for the Discovery and Manufacturing of Human Bispecific Antibodies
Utrecht, The Netherlands, March 9, 2016 - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued three patents related to the generation of bispecific antibodies and to high-throughput functional screening methods of large collections of bispecific antibodies. The patents include claims covering the efficient formation of bispecific antibodies in... 
Printer Friendly Version
01/04/16Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-oncology Applications
Utrecht, The Netherlands and Villejuif, France, January 4, 2016 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced entry into a strategic collaboration to jointly develop bispecific antibodies for therapeutic immuno-oncology applications. Under the terms of the agreement, Merus and Gustave Roussy will collaborate on the design and con... 
Printer Friendly Version

RSS FeedsFinancial Tear SheetE-mail PagePrint PageE-mail Alerts